Literature DB >> 11052419

The epidemiology of respiratory tract infections.

T M File1.   

Abstract

Respiratory tract infections (RTIs) are the most common, and potentially most severe, of infections treated by health care practitioners. Lower RTIs along with influenza, are the most common cause of death by infection in the United States. Risk factors for pneumonia and other respiratory tract infections include: extremes of age (very young and elderly), smoking, alcoholism, immunosuppression, and comorbid conditions. The microbial cause of RTIs vary depending on the infection (i.e., pneumonia compared with acute bacterial sinusitis), setting (i.e., community-acquired compared with nosocomial), and other factors. The causative pathogens associated with CAP have changed in prevalence over time. Although Streptococcus pneumoniae remains the most common causative pathogen, a number of newer pathogens, such as Chlamydia pneumoniae and sin nombre virus, have been recognized in recent years. The emerging antimicrobial resistance of respiratory pathogens (most notably S. pneumoniae) has also increased the challenge for appropriate management of RTI. An awareness of the epidemiology and cause of specific respiratory infections should optimize care.

Entities:  

Mesh:

Year:  2000        PMID: 11052419     DOI: 10.1053/srin.2000.18059

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  18 in total

1.  Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness.

Authors:  Kaharu C Sumino; Michael J Walter; Cassandra L Mikols; Samantha A Thompson; Monique Gaudreault-Keener; Max Q Arens; Eugene Agapov; David Hormozdi; Anne M Gaynor; Michael J Holtzman; Gregory A Storch
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

Review 2.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

3.  High prevalence of respiratory viral infections in patients hospitalized in an intensive care unit for acute respiratory infections as detected by nucleic acid-based assays.

Authors:  Jérôme Legoff; Emmanuel Guérot; Angélique Ndjoyi-Mbiguino; Mathieu Matta; Ali Si-Mohamed; Laurent Gutmann; Jean-Yves Fagon; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles.

Authors:  Mohamed S Arredouani; Zhiping Yang; Amy Imrich; Yaoyu Ning; Guozhong Qin; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-04       Impact factor: 6.914

Review 5.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Vitamin D status and acute respiratory infection: cross sectional results from the United States National Health and Nutrition Examination Survey, 2001-2006.

Authors:  Dominique J Monlezun; Edward A Bittner; Kenneth B Christopher; Carlos A Camargo; Sadeq A Quraishi
Journal:  Nutrients       Date:  2015-03-13       Impact factor: 5.717

7.  Increase in pneumococcus macrolide resistance, United States.

Authors:  Stephen G Jenkins; David J Farrell
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

8.  May we strengthen the human natural defenses with bacterial lysates?

Authors:  Elisa Villa; Valentina Garelli; Fulvio Braido; Giovanni Melioli; Giorgio Walter Canonica
Journal:  World Allergy Organ J       Date:  2010-08       Impact factor: 4.084

9.  Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.

Authors:  F Braido; F Tarantini; V Ghiglione; G Melioli; G W Canonica
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.

Authors:  Keisuke Sunakawa; David J Farrell
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-08-13       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.